COMPARISON OF LOADING DOSE OF CLOPIDOGREL WITH TICAGRELOR IN ELDERLY PATIENTS UNDERGOING PCI IN STABLE ISCHEMIC HEART DISEASE

N AKHUND; DR SHIREEN; Z MALIK; W JAMIL

doi:10.54112/bcsrj.v2023i1.284

Authors

N AKHUND Department of Cardiology, Saidu Group of Teaching Hospitals Swat, Pakistan
DR SHIREEN Department of Cardiology, Liaquat University Hospital, Pakistan
Z MALIK Department of Cardiology, University of Lahore, Pakistan
W JAMIL Department of Cardiology, Chaudry Pervaiz Elahi Institute of Cardiology, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.284

Keywords:

stable ischemic heart disease, Eticagrelor, clopidogrel,, PCI, lderly patients

Abstract

This study aimed to compare the efficacy and safety of loading doses of clopidogrel with ticagrelor in elderly patients undergoing PCI in SIHD. Methods: A randomized controlled trial was conducted at Saidu Group of Teaching Hospitals from January 2019 to January 2020. 600 patients aged 65 years or older with SIHD who underwent PCI were randomized to receive either a loading dose of clopidogrel 600mg or ticagrelor 180mg. The primary endpoint was a composite of death, myocardial infarction, stent thrombosis, or stroke at 30 days post-PCI.Results: The incidence of the primary endpoint was similar in both groups (8.3% in the clopidogrel group vs. 8.2% in the ticagrelor group, P=0.95). There were no significant differences in the rates of individual components of the primary endpoint between the two groups. Bleeding events were also similar in both groups (4.8% in the clopidogrel group vs. 4.7% in the ticagrelor group, P=0.95). However, ticagrelor was associated with a significantly higher incidence of dyspnea (9.8% vs. 2.3%, P<0.001).Conclusion: In elderly patients undergoing PCI for SIHD, a loading dose of clopidogrel was found to be non-inferior to ticagrelor in terms of the composite endpoint of death, myocardial infarction, stent thrombosis, or stroke at 30 days post-PCI.

Downloads

Download data is not yet available.

References

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082-1115.

Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of ticagrelor over clopidogrel in elderly patients with and without diabetes mellitus: insights from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Cardiovasc Interv Ther. 2016;31(2):120-131.

Kang J, Kim HS, Lee JM, et al. Effect of ticagrelor vs. clopidogrel on platelet reactivity and cardiovascular outcomes in elderly patients undergoing coronary intervention: results from the randomized Ticagrelor in Elderly Patients with Acute Coronary Syndrome (TIME) trial. Eur Heart J. 2018;39(40):3639-3646.

Amin AP, Bach RG, Caruso ML, et al. Association of same-day discharge after elective percutaneous coronary intervention in the United States with costs and outcomes. JAMA Cardiol. 2020;5(1):19-27.

Watanabe H, Domei T, Morimoto T, et al. Effect of ticagrelor vs. clopidogrel on platelet reactivity and clinical outcomes in patients undergoing coronary artery bypass grafting: the TiCAB randomized clinical trial. JAMA. 2019;321(24):2428-2437.

Serebruany VL, Atar D. Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol. 2007;99(3):288-290.

Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™.Am J Cardiol. 2011; 107:1136–1143. doi: 10.1016/j.amjcard.2010.12.009

Li C, Liu M, Chen W, Jiang T, Ling L. Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina. Eur J Clin Pharmacol. 2022 Dec;78(12):1949-1958. doi: 10.1007/s00228-022-03401-3. Epub 2022 Oct 17. PMID: 36245047; PMCID: PMC9649465.

Hamilos M, Kanakakis J, Anastasiou I, Karvounis C, Vasilikos V, Goudevenos J, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial. EuroIntervention. 2021;16(14):1163–1169. doi: 10.4244/EIJ-D-20-00268.

Bergmark BA. Real-world comparison of ticagrelor and clopidogrel: Rosetta Stone or lost in translation? J Am Heart Assoc. 2020;9(14):e017888. doi: 10.1161/JAHA.120.017888

Russo JJ, James TE, Ruel M, Dupuis JY, Singh K, Goubran D, et al. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. Eur Heart J Acute Cardiovasc Care. 2019;8(6):543–553. doi: 10.1177/2048872617740832.

Zhang YR, Xue ZK, Chen KY, Xu LX, Wang WD, Tao HY, et al. Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome. Perfusion.